Safety evaluation: adverse events*
| 0.5% Levofloxacin (n=124) | Placebo (n=120) | |
|---|---|---|
| *Reported by at least 2% of patients in either treatment group regardless of relation to study medication. | ||
| Non-ocular: n (%) | ||
| Headache | 7 (5.65) | 2 (1.67) |
| Pharyngitis | 3 (2.42) | 0 (0.00) |
| Ocular: n (%) | ||
| Conjunctivitis | 18 (14.52) | 12 (10.00) |
| Epitheliopathy | 0 (0.00) | 3 (2.50) |
| Burning | 3 (2.42) | 0 (0.00) |
| Discomfort | 0 (0.00) | 3 (2.50) |
| Decreased vision | 4 (3.23) | 3 (2.50) |